ACS is committed to helping combat the global COVID-19 pandemic with initiatives and free resources. Learn More

David J. Donnelly

David Donnelly

David J. Donnelly completed his Ph.D. in Organic Chemistry in 2006 from the University of Buffalo with a focus on the synthesis of sulfur, selenium and tellurium containing rhodamine dyes for use in photodynamic therapy. After receiving his Ph.D. he conducted his post-doctoral research with Professor Mike Kilbourn at the University of Michigan, where he worked on the synthesis and design of both carbon-11 and fluorine-18 PET radioligands for in-vivo PET imaging. During his post doctoral studies he completed the synthesis of more than 20 different PET radioligands for human use such as: [11C]-PIB, [11C]-Carfential, and [18F]-Florbetapir to name a few.  David joined BMS in 2007 where he has focused on the design and synthesis of PET radioligands for use in both drug discovery and drug development process at BMS.  He has recently been involved with the discovery and development of [11C]-BMT-136088,  a PET radioligand used in human lung imaging studies of the LPA-1 receptor.